pharma · Prurigo Nodularis · Vitiligo
Incyte
NovaPharmaNews editorial coverage mentioning Incyte — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 1801 Augustine Cut-Off, Wilmington, Delaware 19803, US
- Employees
- 3,381
- Programs
- 53
- Drugs
- 61
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Incyte — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Incyte — regulatory, clinical, and market analysis.
Lilly’s early JAK data raises myelofibrosis competition question
Eli Lilly reported early positive data for a next-generation JAK inhibitor acquired through Ajax. The readout could position Lilly as a potential future competitor to Incyte’s Jakafi in myelofibrosis.
Incyte's Strategic Positioning of Monjuvi for First-Line DLBCL
Incyte is strategically positioning Monjuvi for first-line treatment of DLBCL, responding to the competitive landscape of bispecific therapies. This article delves into the implications for pharmaceutical teams and investors.
PharmaEssentia's Strategic Move: Eric Vogel Joins to Drive Besremi Expansion
PharmaEssentia has appointed Eric Vogel, a former Incyte executive, to spearhead the expansion of its drug Besremi. This strategic move highlights the company's growth ambitions in the pharmaceutical sector.
Incyte's Strategic AI Partnerships: Implications for Pharma
Incyte has signed significant AI deals with Genesis Molecular AI and Edison Scientific, marking a pivotal moment for its innovation strategy. This article explores the implications for the pharmaceutical landscape.